KaliVir Immunotherapeutics
PrivateLast Round
Series A
Extension
Aug 19, 2026
Total Funding Raised
$29M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
KaliVir Immunotherapeutics operates in Healthcare & Life Sciences and is based in Pittsburgh, Pennsylvania. Its latest recorded funding round was a Series A Extension round in August 2026.
KaliVir Immunotherapeutics is a biotechnology company developing next-generation oncolytic viral immunotherapy programs for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
KaliVir Immunotherapeutics Comparables
Compare KaliVir Immunotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Accession Therapeutics Limited | 87% | |
| Virogin Biotech | 86% | |
| TILT Biotherapeutics | 85% |
For institutional investors. Book with your work email.
KaliVir Immunotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Aug 19, 2026 | ||||
| Series A | Mar 16, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
KaliVir Immunotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Investment | Series A Extension |
| Premier Partners | Series A |
| Nextrans | Series A Extension |
| QUAD Investment Management | Series A Extension, Series A |
| Company K Partners | Series A, Series A Extension |
| Company K Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 48% MoM.
- Aug 19, 2026
$14M round with participation from QUAD Investment Management and SV Investment.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 19, 2026
In Aug '26, KaliVir Immunotherapeutics, Inc. receives $14M in Series A1 financing, an extension of its Series A, led by Company K Partners with participation from SV Investment, Flexus Partners and existing investors including affiliates of Nextrans and Quad Investment Management, to advance VET3-TGI and the STEALTH-001 Phase 1/1b trial in advanced solid tumors.
For institutional investors. Book with your work email.
KaliVir Immunotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about KaliVir Immunotherapeutics's valuation, stock price, and market status.
Is KaliVir Immunotherapeutics a public or private company?
KaliVir Immunotherapeutics is a private company.
What is the current stock price of KaliVir Immunotherapeutics?
KaliVir Immunotherapeutics is a private company, so its shares have no public market price. Caplight tracks KaliVir Immunotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is KaliVir Immunotherapeutics worth (valuation)?
Valuation information for KaliVir Immunotherapeutics is not publicly available.
Can I buy KaliVir Immunotherapeutics stock?
KaliVir Immunotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was KaliVir Immunotherapeutics's last funding round?
KaliVir Immunotherapeutics's most recent funding round was Series A Extension on August 19, 2026.
Who are the main investors in KaliVir Immunotherapeutics?
Key investors in KaliVir Immunotherapeutics include Premier Partners, Company K Partners.
Will KaliVir Immunotherapeutics IPO soon?
No public IPO plans have been announced for KaliVir Immunotherapeutics.
How can I track KaliVir Immunotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in KaliVir Immunotherapeutics's shares on secondary markets.